Physician profile
Charles Malak
NPI 1629583596
$2,871.66
in general payments reported to CMS, 2019-2025
20 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $903 · 2023: $604 · 2024: $907 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $259.77 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.17 | 2024-2025 | Jardiance |
| Sage Therapeutics, LLC | $229.21 | 2023 | |
| Abbvie INC. | $224.79 | 2022-2024 | |
| Edwards Lifesciences Corporation | $167.87 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bioventus LLC | $150.01 | 2024 | Durolane |
| Neurocrine Biosciences, INC. | $130.90 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.57 | 2023 | |
| Gilead Sciences, INC. | $125.00 | 2023 | Epclusa |
| Axsome Therapeutics, INC. | $125.00 | 2024 | Sunosi |
| Biogen, INC. | $125.00 | 2025 | Spinraza |
| Exact Sciences Corporation | $124.03 | 2023 | Cologuard Collection Kit |
| Lexicon Pharmaceuticals, INC. | $123.96 | 2024 | Inpefa |
| Ultragenyx Pharmaceutical INC. | $119.16 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $117.80 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $113.54 | 2022 | |
| Genzyme Corporation | $106.28 | 2024 | |
| Pfizer INC. | $90.23 | 2025 | |
| Scynexis, INC. | $88.49 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $85.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Malak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.